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Abstract
Background: Neuroblastoma is a paediatric cancer that despite multimodal therapy still has a poor outcome for
many patients with high risk tumours. Retinoic acid (RA) promotes differentiation of some neuroblastoma tumours
and cell lines, and is successfully used clinically, supporting the view that differentiation therapy is a promising strategy
for treatment of neuroblastoma. To improve treatment of a wider range of tumour types, development and testing of
novel differentiation agents is essential. New pre-clinical models are therefore required to test therapies in a rapid cost
effective way in order to identify the most useful agents.
Methods: As a proof of principle, differentiation upon ATRA treatment of two MYCN-amplified neuroblastoma cell
lines, IMR32 and BE2C, was measured both in cell cultures and in tumours formed on the chick chorioallantoic membrane
(CAM). Differentiation was assessed by 1) change in cell morphology, 2) reduction in cell proliferation using Ki67 staining
and 3) changes in differentiation markers (STMN4 and ROBO2) and stem cell marker (KLF4). Results were compared
to MLN8237, a classical Aurora Kinase A inhibitor. For the in vivo experiments, cells were implanted on the
CAM at embryonic day 7 (E7), ATRA treatment was between E11 and E13 and tumours were analysed at E14.
Results: Treatment of IMR32 and BE2C cells in vitro with 10 μM ATRA resulted in a change in cell morphology, a 65%
decrease in cell proliferation, upregulation of STMN4 and ROBO2 and downregulation of KLF4. ATRA proved more
effective than MLN8237 in these assays. In vivo, 100 μM ATRA repetitive treatment at E11, E12 and E13 promoted a
change in expression of differentiation markers and reduced proliferation by 43% (p < 0.05). 40 μM ATRA treatment at
E11 and E13 reduced proliferation by 37% (p < 0.05) and also changed cell morphology within the tumour.
Conclusion: Differentiation of neuroblastoma tumours formed on the chick CAM can be analysed by changes in cell
morphology, proliferation and gene expression. The well-described effects of ATRA on neuroblastoma differentiation
were recapitulated within 3 days in the chick embryo model, which therefore offers a rapid, cost effective model
compliant with the 3Rs to select promising drugs for further preclinical analysis.
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Background
Neuroblastoma is a paediatric cancer derived from the
sympathoadrenal lineage and is thought to originate
from undifferentiated neuroblasts [1]. Treatment has ad-
vanced over the last decade or more and now includes
immunotherapy and differentiation therapy alongside
conventional chemotherapy, radiotherapy and surgery.
Overall, survival for patients with high risk neuroblast-
oma tumours is poor (< 50%), thus crucially indicating a
need to develop additional therapies [2, 3]. Whilst many
agents tested in vitro look promising, remarkably few
are as successful in preclinical models or eventually
patients. The most common model used for screening
potential drugs is the mouse xenograft model where
neuroblastoma cells are introduced either subcutane-
ously or orthotopically. Mouse models are expensive and
time consuming hence there is a need for additional
models. These models should be rapid, cost effective and
NC3Rs compliant in order to contribute to the identifi-
cation of novel therapies which have the potential to
progress to successful preclinical/clinical trials and ul-
timately have a significant impact on the disease.
The chick chorioallantoic membrane (CAM) has been
used for many years to support the growth of tumours
including neuroblastoma [4]. It has been especially at-
tractive as a model for studying angiogenesis due to the
accessibility and visibility of the blood vessels drawn in
to support tumour growth. Drugs to investigate and ma-
nipulate angiogenesis have been supplied in various for-
mats including within plastic rings and gelatin sponges
[5]. The ability of cells to form tumours on the CAM
has also been used to investigate tumour biology such as
the ability of tumour cells to invade and metastasise into
the embryo [6–8] and most recently the CAM tumour
model is increasingly finding a use as a platform to ana-
lyse the effectiveness of anticancer drugs on invasion
and metastasis [9–11].
One characteristic feature of neuroblastoma is its un-
usually high rate of spontaneous regression and this may
be connected to the susceptibility of tumour cells to dif-
ferentiate. Indeed tumours with a differentiating hist-
ology and markers of mature neurons such as TrkA are
low risk whilst tumours with undifferentiated histology
are high risk [12, 13]. A small number of genetic muta-
tions have been identified in neuroblastoma tumours,
the first and best characterised is amplification of a vari-
able sized amplicon containing the MYCN gene [14]. A
number of neuroblastoma cell lines (typically MYCN-
amplified (MNA)) have been shown in culture to slow
or cease cell division and begin to extend axons in re-
sponse to retinoic acid (RA). We have previously shown
similar differentiation responses by the MNA cell lines
Kelly and SK-N-BE2(C) triggered by the embryonic en-
vironment of the chick [15]. Thus differentiation therapy
is a promising approach for treating high risk neuro-
blastoma and whilst some tumours and cell lines remain
resistant to RA, MNA cell lines generally respond well.
Here we have used ATRA in culture as a proof of
principle to validate suitable assays and timescale of re-
sponse of tumours formed on the chick CAM. We show
that ATRA reduces cell proliferation and increases differ-
entiation of MNA Neuroblastoma tumours within 3 days
thus establishing the CAM tumour model as a suitable in
vivo model for screening new differentiation therapies.
Methods
Cell culture
SK-N-BE(2)C (human NB, ECACC No. 95011817) and
IMR-32 (human NB, ECACC No. 86041809) were grown
in DMEM (Life Technologies), 10% Foetal Bovine Serum
(Biosera, East Sussex, UK), 100 U/ml penicillin,100 μg/
ml streptomycin (Sigma, P0781) and 1% Non-Essential
Amino Acids (Sigma, M7145). They were maintained at
37 °C with 5% CO2 in humidified incubator. Passaging
was carried out using 0.05% Trypsin/EDTA (Sigma
Aldrich) as required. Cell lines were transduced with
green fluorescent protein (GFP) lentivirus as described
previously [7, 15].
Morphology analysis and cell proliferation assays
1 × 104 of BE(2)C cells and IMR32 cells were plated onto
coverslips in a 24 well plate, incubated for 18-24 h.
Medium containing either 10 μM RA, 4 μM of
MLN8237 or DMSO alone 0.06% or 0.04% final concen-
tration was added and cells were analysed after 72 h of
incubation. To assess the morphology of cells, images of
cells were obtained using an inverted microscope (Leica
DMIRB) prior to fixation. For immunocytochemistry,
coverslips were removed from wells and fixed with 4%
paraformaldehyde for 10 min, blocked with 1% BSA,
0.1% Triton X100 in 0.12 M phosphate pH 7.4 for
30 min and stained overnight at 4 °C with 1:50 dilution
of Ki67 (Abcam ab16667) followed by 1:500 Goat anti
rabbit Alexa 594 (Life Technologies) for one hour at
room temperature both diluted in blocking buffer. Cell
nuclei were stained with DAPI. Proliferating cells were
quantified by Ki67 staining and normalised to the total
number of nuclei stained by DAPI. At least three fields
per coverslip and 3 coverslips per experiment were
counted and a minimum of 300 cells per condition.
Chick embryo CAM assays
Fertilised white leghorn chicken eggs were obtained
from Lees Lane Poultry, Wirral, or Tom Barron, Preston,
UK. Eggs were incubated at 38 °C and 35–40% humidity
and windowed at E3 as described previously [15]. GFP-
labelled cells were initially seeded onto the CAM as
tumourspheres, in matrigel or as a cell suspension.
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A cell suspension of 2 × 106 in 5 μl of DMEM
seeded onto a slightly injured CAM was found to be
most efficient [7]. The CAM was injured by laceration
with a pipette tip or traumatisation using a strip of sterile
lens tissue causing small bleed [16]. Traumatisation was
found to be the most reproducible method and was used
for all experiment. To further enhance the efficiency of
tumour formation 5 μl of 0.05% trypsin 0.5 mM EDTA
was added immediately prior to the addition of cells. For
confocal analysis, 10% GFP with 90% unlabelled cells were
used to facilitate observing any morphological changes in-
side the tumours. Eggs were resealed and incubated until
E11 [17].
Drugs administration
Embryos were treated either topically to the CAM or by
injection into the allantoic cavity between E11 and E13.
ATRA was used at 10 μM and 100 μM for 3 days at E11,
E12 and E13 or 40 μM was used at E11 and E13.
Concentration was determined based on the volume of
an egg of 45 ml. 2.8 μl, 11.25 μl or 28 μl DMSO diluted
to 200 μl in PBS was injected into control embryos.
Embryos were dissected on E14 and tumours analysed.
Quantitative PCR
In vitro samples: Each cell line was seeded at a density
of 2 × 106 per 75cm2 flask and after 24 h, medium was
replaced with fresh medium containing either ATRA
(10 μM) or MLN8237 (4 μM) or DMSO. Every 48 h the
medium was replaced with fresh medium containing
RA, MLN8237 or DMSO. After 3 or 6 days, RNA was
extracted using RNA mini Kit (QIAGEN) according to
manufacturer’s instructions. qPCR was carried out on
CFX Connect (Biorad) thermocycler using iTaq Universal
SYBR green mix (Biorad) 0.5 μM primers and up to 2 μl
cDNA for 35 cycles. An annealing temperature of
60 °C was used for all primer pairs and three tech-
nical replicates and three biological replicates were
carried out for each sample. qPCR data analysis was
carried out using Bio-Rad CFX Manager 3.0 software.
Normalised relative expression of target genes was
calculated using the ΔΔCq analysis mode. A list of
the primers used is provided in Table 1.
In-vivo tumours: Tumours were harvested from the
CAM, rinsed in phosphate-buffered saline (PBS), then
transferred into RNAlater solution (QIAGEN), and
stored at initially at 4 °C or −20 °C for longer term stor-
age prior to RNA extraction. Tissue was first removed
from the RNAlater and transferred to a clean RNase free
falcon tube. Liquid nitrogen was used to freeze the tissue
before a pestle and mortar was used to disrupt it. RNA
was then extracted using RNA mini Kit (QIAGEN).
qPCR was performed as described above.
Immunohistochemistry
Tumours which were harvested for paraffin embedding
were fixed overnight in 10% neutral buffered formalin
and embedded in paraffin using standard protocols.
Prior to staining, the slides underwent deparaffination
and high temperature antigen retrieval using a DAKO
PT link. Following antigen retrieval, the slides were in-
cubated in EnvisionTM FLEX Wash Buffer (1× working
solution pH 7.67; DAKO, K8007) for 5 mins prior to
loading onto the DAKO Autostainer (K8012). Sections
were incubated for 30 min with Ki67 antibody (1:200)
(DAKO M7240) in 5% BSA in Tris Buffered Saline
followed by goat anti-mouse HRP (Abcam) and staining
with 3,3′-diaminobenzidine. Haematoxylin staining was
performed on all the slides and some slides were also
stained with eosin to assist in distinguishing between
tumour and chick nuclei. A total of 12 fields from 3
slides were counted per tumour and at least two tu-
mours per condition were analysed.
Morphology analysis
Tumours required for confocal imaging were fixed in 4%
paraformaldehyde for one hour, trimmed into small
pieces <2mm3 and mounted into slides using DAKO
mounting medium. The images were observed using the
Leica DMIRE2 microscope at X40 objective to assess the
morphology of cells within the tumours.
Table 1 List of primers used for qPCR analysis
Gene Gene name Forward 5′-3′ Reverse 5′-3′
UBC ubiquitin C ATTTGGGTCGCGGTTCTTG TGCCTTGACATTCTCGATGGT
HPRT1 hypoxanthine phosphoribosyltransferase 1 TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT
GAPDH glyceraldehyde-3-phosphate dehydrogenase AATCCCATCACCATCTTCCA TGGACTCCACGACGTACTCA
ROBO2 roundabout, axon guidance receptor, homolog 2 GATGTGGTGAAGCAACCAGC TGGCAGCACATCTCCACG
STMN4 stathmin-like 4 CCTAGCAGAGAAACGGGAACA GGCGTGCTTGTCCTTCTCTT
KLF4 Kruppel-like factor 4 CGCCGCTCCATTACCAAGAGC
CGGTCGCATTTTTGGCACTG
CGGTCGCATTTTTGGCACTG
MYCN Neuroblastoma-derived v-myc avian myelocytomatosis
viral related oncogene
CACAAGGCCCTCAGTACCT ACCACGTCGATTTCTTCCTCT
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Statistical analysis
Statistical significance was computed using Student’s
t-test or one-way ANOVA followed by a post-hoc tukey
test using SPSS. All data are presented as mean + S.E.M.
(standard error of the mean).
Results
Assessment of ATRA effects by measuring cell
proliferation and expression of differentiation markers
The effect of ATRA on MNA neuroblastoma cells has
been well characterised in terms of morphology and im-
munofluorescence of differentiation markers [18–20].
We wished to develop assays that would enable us to
quantify the extent of differentiation upon drug treat-
ment and be suitable to compare effects in culture and
in CAM tumours. Differentiation usually goes in parallel
with a decrease in proliferation, which can be measured
by Ki67 staining. The expression of differentiation and
stem cell markers allows direct quantification of the dif-
ferentiation process and can be assessed by qPCR. Two
MNA cell lines BE2C and IMR32 were selected as they
respond well to RA. In cell culture, 10 μM ATRA treat-
ment for 3 days prompted the expected change in
morphology (Fig. 1a) and a 65% decrease in the prolifer-
ation rate in both cell lines (Fig. 1b–d). The expression
of two differentiation markers (STMN4 and ROBO2)
and one stem cell marker (KLF4) was further analysed
by qPCR. These three markers have previously been
shown to exhibit significant changes in IMR32 cells in
response to ATRA by qPCR [21]. Here, STMN4
a
b c
d
Fig. 1 ATRA promotes a reduction in cell proliferation and change in morphology in IMR-32 and BE(2)C cells. a Morphological changes in IMR-32
and BE(2)C after 3 days of treatment with 10 μM ATRA (RA), an enlarged view of IMR-32 cells is displayed showing a number of cellular extensions
of variable length. b DAPI stained (blue) and Ki67 stained (red) BE(2)C cells following three days of treatment with 10 μM ATRA or DMSO (control).
c DAPI stained (blue) and Ki67 stained (red) IMR-32 cells following three days of treatment with 10 μM ATRA or DMSO. d Graph to show the reduction
in cell proliferation following treatment with ATRA. Each bar represents three biological replicates and at least 9 fields per experiment. ** p < 0.01
and ***p < 0.001. Error bars are standard error (SE). Scale bar is 100 μM
Swadi et al. BMC Cancer  (2018) 18:28 Page 4 of 11
increased more than 6 fold (p < 0.001) and KLF4 de-
creased by 5.5 fold (p < 0.05) in IMR32 treated with
ATRA for 3 days (Fig. 2a). A non-significant increase in
ROBO2 and small decrease in MYCN expression was
also observed. The results with BE2C cells were similar
(Fig. 2a). To test whether the changes with ROBO2 and
MYCN would become significant we treated both cells
lines with ATRA for 6 days in culture. By this stage
ROBO2 was significantly up regulated in both cell lines
and MYCN was significantly down regulated confirming
the trends observed at three days (Fig. 2b).
Comparison of ATRA effects with an aurora a kinase
inhibitor, MLN8237 on neuroblastoma cell differentiation
Aurora A kinase has been shown to stabilise MYCN [22]
and early results in preclinical models have proven
promising with data suggesting that MLN8237 might re-
duce MYCN protein levels, decrease cell proliferation and
increase differentiation of Neuroblastoma cells [23, 24].
We tested whether this drug was more effective than RA,
prior to further validation of drug delivery to the CAM tu-
mours. We tested 1, 4 and 10 μM MLN8237 in both cell
lines. Whilst 10 μM showed some toxicity, 4 μM showed
some change in morphology after 3 days (Fig. 3a).
MLN8237 also reduced cell proliferation by 22% (BE2C)
and 24% (IMR32) a much smaller extent than with ATRA
(Fig. 3b). The qPCR results showed no significant change
for any of the markers after 3 days treatment in
culture although similar trends as for ATRA were ob-
served (Fig. 3c). ATRA was therefore used for subse-
quent in vivo experiments.
Optimisation of tumour formation onto the CAM, for a
wide range of neuroblastoma cell lines
Some cell lines efficiently form tumours on the CAM
whilst others, including BE2C and IMR32, do so less fre-
quently [25]. This was surprising since MNA cells are
thought to be both aggressive and invasive cells and
BE2C and Kelly cells readily extravasate into the embryo
following intravenous injection [15]. SKNAS cells form
tumours efficiently [7] and BE2C cells mixed with
SKNAS cells also formed tumours. However BE2C or
IMR32 cells alone more typically formed a sheet of dried
cells on the surface of the CAM (data not shown), sug-
gesting that the cells lacked invasive potential. This
prompted us to test treating the CAM surface with tryp-
sin immediately prior to adding the cells to facilitate
invasion and this indeed improved the efficiency of
tumour formation for BE2C cells to more than 70%
(Fig. 4a). Trypsin treatment also improved the efficiency
of tumour formation for IMR32 and Kelly cells although
these remained less efficient than BE2C cells. Tumours
formed beneath the surface of the CAM became visible
under the fluorescent stereomicroscope within 3–4 days
and reached 1-5 mm in size by E14 (Fig. 4b-c). Tumours
had clearly recruited blood vessels from the surrounding
CAM and were highly vascularised although the IMR32
tumours were less vascularised than the BE2C. The hist-
ology of the tumours formed reflected the histology of
patient tumours suggesting the tumours are a good
model for preclinical analysis (Fig. 4d).
RA promotes differentiation and reduces proliferation of
BE2C and IMR32 tumours
Tumours could be reliably observed by E11 so ATRA
treatment was initiated at E11 and repeated at E12 and
E13. The volume of eggs was approximately 45 ml and
ATRA was added to give a final concentration of
100 μM which was equivalent to 30 mg/kg used for
treating mouse xenograft tumours [26]. ATRA is insol-
uble in aqueous solutions however survival of embryos
is compromised by more than 100 μl of DMSO and by
the addition of 100% DMSO [27]. Hence the ATRA di-
luted in maximally 28 μl of DMSO was further diluted
a
b
Fig. 2 ATRA up-regulates differentiation markers ROBO2 and STMN4
and down-regulated the stem cell marker KLF4 in IMR-32 and BE(2)C
cells. Relative mRNA levels for the target genes was determined by
qPCR. a Graph displays the level of target gene expression in BE(2)C
and IMR-32 cells after 3 days of ATRA (RA) treatment (10 μM) relative
to DMSO treated cells, b shows the change in expression after 6 days
of treatment with RA. Each bar in the graph represents the mean of
technical replicates and three biological repeats. Error bars are SE (T-test).
* p< 0.05, ** p< 0.01, *** p< 0.001
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up to 200 μl with PBS to form a colloidal suspension.
Topical addition of the suspension was used success-
fully in some experiments however in some cases
not all the ATRA re-dissolved. Hence, in later exper-
iments the colloidal suspension was injected into the
allantoic sac where it reproducibly dissolved within a
few hours, aided by the movements of the chick em-
bryo. Tumours treated with and without ATRA were
analysed for changes in the differentiation markers
and also for MYCN (Fig. 5a). For IMR32 cells, the
results were similar to those observed in culture,
with KLF4 down regulated 4.2 fold and STMN4
upregulated 4.4 fold (p < 0.05). ROBO2 and MYCN
showed an appropriate trend that although it was
not statistically significant. For BE2C cells both
ROBO2 and STMN4 were significantly upregulated
(5.9 fold and 5.0 fold respectively; p < 0.05) and
KLF4 and MYCN were down regulated by 3.4 and
2.2 fold respectively although these latter results
were not statistically significant. Survival of the em-
bryos was unaffected by the introduction of ATRA
compared to either 28 μl of DMSO per injection or
no treatment (Fig. 5b).
The effect of ATRA on cell proliferation of BE2C cells
within the tumour was also assayed. The percentage of
dividing cells was reduced by 43% compared to the
DMSO control (Fig. 6a). Treatment of tumours with
100 μM every 24 h was a considerably higher dose than
the 10 μM every 48-72 h used in culture. We therefore
tested the effect of lower doses of ATRA. As shown
in Fig. 6b, 10 μM ATRA (3 doses) reduced prolifera-
tion by 22% (not significant) while 40 μM (2 doses at
E11 and E13) reduced proliferation by 37% (p < 0.05)
(Fig. 6b and c). Thus four times the dose used in cul-
ture was sufficient to produce statistically significant
results in vivo (Fig. 6c).
Finally we sought to test whether 40 μM ATRA would
also change the morphology of cells within the tumour
as is typically observed in culture. For this experiment,
only 10% of the cells within the tumour expressed GFP
with the remaining 90% were unlabelled BE2C cells.
Confocal images of tumours treated with ATRA or
DMSO are shown in Fig. 6d. ATRA treated cells exhib-
ited a more elongated shape with cells often having
small extensions resembling neurites.
Taken together these results demonstrate, using ATRA
as a proof of principle, that the chick CAM model can
be used successfully for drug treatment thereby provid-
ing a platform of choice for further evaluation of drug
efficiency in neuroblastoma.
Discussion
The chick embryo has been used extensively to study de-
velopment however its use for investigating cancer biol-
ogy, especially its value for testing the efficacy of drugs,
has been more limited to date [9–11]. The chick embryo
also complies with widely accepted guidelines designed
to reduce animal numbers, refine and replace animal
models (the 3Rs) [28]. In our experiments we introduce
cells onto the CAM at E7, the earliest time point at
which the CAM is sufficiently developed, and complete
experiments at E14. Hence these experiments, although
in vivo, are not considered animal experiments under
UK legislation and thus replace the use of animals.
Many cell lines form tumours on the CAM however
some do not [25, 29] a feature we have also observed
a
b
c
Fig. 3 The effect of MLN8237 treatment on IMR-32 and BE(2)C cells.
a Morphological changes of both cell lines after 3 days of 4 μM
MLN8237 treatment. b shows the percentage change in proliferating
cells in IMR-32 and BE(2)C following treatment with 4 μM MLN8237
for 3 days. c qPCR analysis of changes in target gene expression fol-
lowing 3 days of treatment. Each bar represents the mean of 3 tech-
nical replicates and 3 biological replicates. Although the trend in the
changes of gene expression are the same as for ATRA the fold change
is smaller and does not reach significance. Error bars (SE). Scale
bar 100 μM
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with Neuroblastoma cell lines. Tumour cells need to in-
vade through the epithelial sheet of the CAM and this
may require functioning MMPs to be secreted by the
tumour cells. Whilst many Neuroblastoma secrete MMPs
only SKNAS cells, of those tested, also expressed the bio-
logical activator [30]. This provides an explanation for the
greater efficiency of tumour formation by SKNAS cells [7]
and the rationale for the use of trypsin to enhance tumour
formation for IMR32, Kelly and especially BE2C cells. Use
of trypsin may enhance the use of the CAM tumour
model by expanding the range of cell lines that will form
tumours efficiently.
Drugs can be introduced to the embryo and extra em-
bryonic tumours by topical addition, intravenous (IV) in-
jection or injection into the allantois [31]. We compared
topical addition against IV injection using 5-ethynyl-2′-
deoxyuridine (EdU) and found similar numbers of EdU
labelled cells in the CAM tumour and the liver of the
embryo within 24 h [32]. Indeed given that drugs, by de-
sign, pass into and out of blood vessels it would be
a
c 
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Fig. 4 Tumour formation in chick embryo model. a Tumour formation in the chick embryo with and without the addition of trypsin/EDTA. Percentage
tumour formation was calculated by dividing the number of eggs with tumours at E14 by the total number of embryos surviving until that
time (between 30 and 40 embryos for each cell line and condition were analysed). b GFP images showing IMR-32 BE(2)C and Kelly tumours that
have formed under the CAM. Note the smaller size of the Kelly tumours. c dissected IMR-32 and BE(2)C tumours viewed with GFP fluorescence with
their corresponding bright field image. Note the chick CAM tissue that surrounds each tumour. d H&E staining of BE(2)C tumour FFPE sections. Black
arrows indicate chick tissue. White arrows indicate tumour tissue. Scale bar is 250 μM
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surprising if there was a significant difference between
the two delivery methods. Since IV injections are tech-
nically more difficult we did not pursue this as a delivery
method. For water-insoluble drugs such as ATRA we
found that the allantoic sac provided the optimum
method of delivering drugs since colloids have the op-
portunity to redissolve and be distributed through the
egg aided by the movements of the embryo. One limita-
tion in introducing drugs into embryos is their solubility.
Water soluble drugs are not a problem however DMSO
is a typical solvent for water-insoluble drugs and chick
embryos will tolerate no more than 100 μl of DMSO
[27] and do not tolerate the introduction of 100%
DMSO. We circumvented the insolubility of ATRA by
forming a DMSO:PBS ATRA colloidal mixture and
injecting this into the allantoic sac.
RA was used for our experiments since MLN8237 was
less effective as a differentiation agent for culture BE2C
and IMR32 cells despite reports of good results with tu-
mours formed by the TH-MYCN mouse [23] and xeno-
grafted mice [24]. Tumour formation for BE2C cells can
be reproducibly observed by fluorescent microscopy by
E11 so ATRA injections commenced from E11. ATRA is
used in culture at 10 μM replenished every 48-72 h
whilst in mice a daily dose of approximately 100 μM
(30 mg/kg) is delivered by oral gavage [26]. Initial exper-
iments were carried out using this higher dose about 10
fold greater than used in vitro. Embryos tolerated this
dose well and changes in differentiation markers were
similar to cultured cells while the reduction in prolifera-
tion was somewhat less than observed in vitro.
Nevertheless we were interested to determine the dose
required to observe statistically significant effects of
ATRA and whilst a daily dose of 10 μM ATRA showed
the appropriate trend it required two doses of 40 μM
ATRA at E11 and E13 to give statistically significant
changes in proliferation and a change in cell morph-
ology. This fourfold increase over the concentration
used in culture may be due to sequestration of the
ATRA by the receptors present in cells in the embryo
[33] thus potentially reducing the effective concentra-
tion. In addition, the cells within the tumour maybe less
responsive than those in culture; perhaps reflecting the
differing microenvironment [34].
RA is already established as an effective drug for clin-
ical use [35] however some tumours and cell lines are
resistant and for others the response is incomplete. Here
we have established a method of enhancing tumour
development on the CAM, delivering water-insoluble
drugs to the tumours and three outcomes that confirm
differentiation of cells (qPCR of differentiation markers,
reduction in proliferation and change in cell morph-
ology). Chick embryos develop rapidly with a window of
only 7 days between a sufficiently developed CAM (E7)
and the age embryos come under UK Home Office regula-
tion (E14). Nevertheless tumours can form on the CAM
and respond to drug treatments in this time window mak-
ing the model highly time efficient. It is especially useful
for analysing the cellular response to drug treatment as
changes in gene expression, leading to different cell behav-
iours typically occur on a time scale of hours to days.
These changes rather than, for example, changes in
tumour size suit the short term nature of the model. We
can now extend our results in order to rapidly and cost ef-
fectively test other putative differentiation agents alone or
in combination with RA. Furthermore we have recently
shown that neuroblastoma cells will metastasise into the
embryo following preconditioning in hypoxia [7]. It will
be interesting to discover whether ATRA or other differ-
entiation agents can reverse the effect of hypoxia and
reduce or inhibit the metastasis of Neuroblastoma cells.
Conclusions
40 μM ATRA (4 times the concentration used in cul-
ture), injected into the allantoic sac of a chick embryo,
reduces proliferation of neuroblastoma cells in tumours
formed on the chick CAM within three days and changes
a
b
Fig. 5 ATRA promotes the differentiation of tumours without affecting
chick embryo survival. a. qPCR analysis of changes in relative target
gene expression following daily treatment of 100 μM ATRA at E11, 12
and 13. Each bar in the graph represents the mean of three biological
repeats. ROBO2 and STMN4 show statistical significant changes for
BE(2)C and KLF4 and STMN4 show significant changes for IMR32.
*p < 0.05. Error bars are SE. b. Neither DMSO (28 μl injections X3)
nor ATRA (100 μM injections X3) affected the survival of the chick
embryos (n > 30 for all conditions)
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cell morphology. 100 μM ATRA promotes changes in dif-
ferentiation markers within three days. These results con-
firm that ATRA treatment of tumours formed on the
chick CAM are comparable to those observed in mouse
xenograft tumours [36]. Thus we have established an effi-
cient and robust protocol for using tumours formed on
the chick embryo CAM to test novel therapies. The model
is highly cost effect compared to the mouse xenograft
model, is rapid and 3Rs compliant.
Abbreviations
ATRA: All-trans retinoic acid; BPS: Phosphate buffered saline; BSA: Bovine
serum albumin; CAM: Chorioallantoic membrane; cDNA: Complementary
deoxyribonucleic acid; DAPI: 4′,6-diamidino-2-phenylindole; DMEM: Dulbecco’s
modified eagle medium; DMSO: Dimethyl sulfoxide; EdU: 5-ethynyl-2′-
deoxyuridine; FFPE: Formalin-fixed paraffin-embedded; GAPDH: Glyceraldehyde-
3-phosphate dehydrogenase; GFP: Green fluorescent protein;
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locytomatosis viral related oncogene; NB: Neuroblastoma; QPCR: Quantitative PCR;
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STMN4: Stathmin-like 4; TrkA: Tropomyosin receptor kinase A; UBC: Ubiquitin C
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Fig. 6 Retinoic acid reduces cell proliferation and alters cell morphology in tumours. a. FFPE sections stained with Ki-67. Tumours were treated
with 100 μM ATRA at E11, E12 and E13 and compared to the control which was treated with the equivalent volume of DMSO, b. FFPE sections
stained with Ki-67. Treatments were 10 μM ATRA (10 μM at E11, E12 and E13), 40 μM ATRA (40 μM at E11 and E13) and 100 μM ATRA (100 μM at
E11, E12 and E13). Note the decreasing number and staining intensity of the cell nuclei as the concentration of ATRA is increased. c. Table showing
the quantification of the proliferative cells in BE(2)C tumours after different ATRA treatments. Results suggested that both 40 μM of ATRA (2 injections)
and 100 μM (3 injections) reduces the number of proliferative cells significantly (*p < 0.05) compared to the control. d confocal image of tumour
treated with 40 μM (×2) ATRA or DMSO. Tumours were formed from BE(2)C cells of which 10% expressed GFP. Morphological changes were observed
in some of the ATRA treated tumour cells
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